Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Structure Therapeutics (NasdaqGM:GPCR) reported positive topline Phase 2 results for its oral GLP-1 receptor agonist ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety signals. Read more on GPCR stock.

ACCG-2671 is an oral small molecule amylin receptor agonist which acts through complementary satiety pathways in the ...

Elk Marketing reports that structured data enhances AI understanding, enabling accurate entity recognition and improved ...

As a drug moves through research and regulatory processes, any mistakes in the data will be compounded. Small gaps that a ...

A wholly foreign‑owned enterprise (WFOE) remains the preferred entry structure for many foreign investors in China in 2026.

McGough Construction Vice President of National Operations Derek Hoeschen discusses the firm's processes for building data centers of all sizes.

As data centers continue to proliferate across the country, here’s how Los Angeles County cities are grappling with the ...

Real-world data is increasingly used to optimize trial design, reduce recruitment burden, and support regulatory decisions, but adoption remains uneven due to challenges around data quality, ...

Understanding what contracts are doing may become one of the most important operational capabilities an enterprise can ...